Meta-Analysis
doi: 10.1016/j.diabres.2015.10.014.
Epub 2015 Oct 23.
Incretin-based therapies are associated with acute pancreatitis: Meta-analysis of large randomized controlled trials
Affiliations
- PMID: 26643128
- DOI: 10.1016/j.diabres.2015.10.014
Item in Clipboard
Meta-Analysis
Incretin-based therapies are associated with acute pancreatitis: Meta-analysis of large randomized controlled trials
Diabetes Res Clin Pract.
2015 Dec.
Abstract
Previous studies have offered weak and conflicting evidence regarding the impact of incretin-based oral antihyperglycemic agents on risk of acute pancreatitis. This meta-analysis of three recent mega-trials found an 82% increase in the odds of acute pancreatitis with the use of these agents compared to usual care (95% CI, 1.17-2.82).
Keywords: Acute pancreatitis; DDP4 inhibitors; Gliptins; Incretins; Safety.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.
Similar articles
-
Q: Do incretin drugs for type 2 diabetes increase the risk of acute pancreatitis?Cleve Clin J Med. 2010 Aug;77(8):503-5. doi: 10.3949/ccjm.77a.09167. Cleve Clin J Med. 2010. PMID: 20682512 No abstract available.
-
Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.Cardiovasc Diabetol. 2017 Mar 1;16(1):31. doi: 10.1186/s12933-017-0512-z. Cardiovasc Diabetol. 2017. PMID: 28249585 Free PMC article.
-
The safety of incretin based drugs.BMJ. 2014 Apr 24;348:g2779. doi: 10.1136/bmj.g2779. BMJ. 2014. PMID: 24764568 No abstract available.
-
Using real-world data to evaluate the association of incretin-based therapies with risk of acute pancreatitis: a meta-analysis of 1,324,515 patients from observational studies.Diabetes Obes Metab. 2015 Jan;17(1):32-41. doi: 10.1111/dom.12386. Epub 2014 Oct 6. Diabetes Obes Metab. 2015. PMID: 25200423
-
Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.Ann Pharmacother. 2013 Apr;47(4):490-505. doi: 10.1345/aph.1R444. Epub 2013 Apr 2. Ann Pharmacother. 2013. PMID: 23548652 Review.
Cited by
-
Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.Nat Rev Endocrinol. 2016 Oct;12(10):566-92. doi: 10.1038/nrendo.2016.86. Epub 2016 Jun 24. Nat Rev Endocrinol. 2016. PMID: 27339889 Review.
-
Liraglutide use and evaluation of pancreatic outcomes in a US commercially insured population.Diabetes Obes Metab. 2019 Aug;21(8):1837-1848. doi: 10.1111/dom.13739. Epub 2019 May 24. Diabetes Obes Metab. 2019. PMID: 30945402 Free PMC article.
-
Efficacy and Safety of Once-Weekly Semaglutide for the Treatment of Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Front Pharmacol. 2018 Jun 4;9:576. doi: 10.3389/fphar.2018.00576. eCollection 2018. Front Pharmacol. 2018. PMID: 29915538 Free PMC article.
-
Dipeptidyl peptidase-4 inhibitors, pancreatic cancer and acute pancreatitis: A meta-analysis with trial sequential analysis.Sci Rep. 2018 Jan 15;8(1):782. doi: 10.1038/s41598-017-19055-6. Sci Rep. 2018. PMID: 29335646 Free PMC article.
-
Obesity and pancreatitis.Curr Opin Gastroenterol. 2017 Sep;33(5):374-382. doi: 10.1097/MOG.0000000000000386. Curr Opin Gastroenterol. 2017. PMID: 28719397 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
